Colorectal Cancer

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses the inhibition of heat shock protein 90 (Hsp90) in advanced solid tumors.

Axel Grothey, MD, from the Mayo Clinic in Rochester, Minnesota, discusses the effectiveness of bevacizumab beyond disease progression in metastatic colorectal cancer.

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses the use of ziv-aflibercept (Zaltrap) for patients with metastatic colorectal cancer.

A consensus panel issues a set of discharge warning instructions regarding colorectal surgery.

Axel Grothey, MD, from the Mayo Clinic, Rochester, Minnesota, discusses a survey that examined the perceived benefits and use of adjuvant oxaliplatin in colon cancer.

Paul Ruff, MD, from the Witwatersrand, Johannesburg, South Africa, discusses a time-course analysis of overall survival following treatment with ziv-aflibercept in patients with metastatic colorectal cancer, as observed in the VELOUR trial.

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses studies investigating regorafenib (Stivarga) in metastatic colorectal cancer.

Patients with metastatic colorectal cancer whose disease had progressed despite treatment with oxaliplatin experienced an improvement in survival by switching to a regimen of ziv-aflibercept plus FOLFIRI.

Axel Grothey, MD, from the Mayo Clinic, Rochester, Minnesota, discusses the time course of adverse events following treatment with regorafenib, as observed in the CORRECT study.

William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from a study that examined the association of intrinsic subtypes of colorectal cancer with prognosis, chemotherapy response, and other factors.

Using a new classification system that categorizes colorectal cancers by tumor gene expression patterns, researchers have determined that tumor prognosis and response to adjuvant chemotherapy in CRC vary according to molecular subtype.

A combination of maintenance bevacizumab plus standard second-line chemotherapy appears to be an effective strategy in managing patients with metastatic colorectal cancer after disease progression

Randall F. Holcombe, MD, Tisch Cancer Institute at Mount Sinai Medical Center, speaks about the use of aflibercept in patients with metastatic colorectal cancer.

The prognosis for patients with colorectal cancer has benefited greatly from the advent of advances in chemotherapy and new agents, with nearly threefourths of stage I patients surviving for at least 5 years after diagnosis.

Researchers have identified a potential predictive marker for survival in cases of metastatic colorectal cancer (mCRC) treated with bevacizumab (Avastin), suggesting that patients who have the appropriate biomarker could experience a greater benefit when given the drug, whereas others who do not express the biomarker could be spared from receiving unnecessary therapy.

Randall F. Holcombe, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the oral multikinase inhibitor regorafenib for patients with metastatic colorectal cancer.

Researchers have identified a potential predictive marker for survival in cases of metastatic colorectal cancer treated with bevacizumab.

Computer-aided computed tomographic colonography that does not require a laxative preparation nearly rivals conventional optical colonoscopy for identifying asymptomatic adults with adenomas.

Nancy L. Lewis, MD, from the Thomas Jefferson University Hospitals, discusses the phase III CORRECT trial that examined the multitargeted tyrosine kinase inhibitor regorafenib.

Patients 75 years of age or older with stage III colon cancer may expect a survival benefit from adjuvant chemotherapy that rivals that previously reported in younger patients.

Patients with heavily pretreated metastatic colorectal cancer who received regorafenib experienced a sustained survival benefit across all prespecified subgroups.

The FDA has approved regorafenib, an oral multikinase inhibitor, to treat patients with metastatic colorectal cancer whose disease has progressed after prior therapy.

Colonoscopy is effective for the prevention of colorectal cancer deaths, according to the results of a large, population-based, case-control study.

The oral multikinase inhibitor regorafenib extended OS in patients with metastatic colorectal cancer and improved PFS in patients with gastrointestinal stromal tumors.

The FDA announced that aflibercept has been approved to treat metastatic colorectal cancer when given in combination with the FOLFIRI chemotherapy regimen.